|Ms. Paula Brown Stafford M.P.H.||Pres, CEO & Chairwoman||897.86k||N/A||1965|
|Mr. John M. Gay CPA||CFO & Corp. Sec.||408.03k||N/A||1976|
|Mr. Andrew J. Novak||VP of Accounting & Bus. Operations and Chief Accounting Officer||N/A||N/A||N/A|
|Dr. Carri Geer Ph.D.||Sr. VP & CTO||N/A||N/A||N/A|
|Mr. Cole Ikkala||Director of Investor Relations, Communications & Bus. Devel.||N/A||N/A||N/A|
|Mr. Stanley Hollenbach BS,J.D.||Sr. VP of R&D||N/A||N/A||N/A|
|Mr. Brian M. Johnson||Chief Commercial Officer||N/A||N/A||1966|
|Dr. Tomoko Maeda-Chubachi M.B.A., M.D., Ph.D.||Chief Medical Officer||N/A||N/A||N/A|
|Ms. Elizabeth Messersmith||Sr. VP & Chief Devel. Officer||N/A||N/A||N/A|
Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is based in Durham, North Carolina.
Novan, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.